RS
LAB icon

R Squared’s Standard BioTools LAB Stock Holding History

R Squared’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.44K Buy
+10,268
New +$12.4K 0.01% 471
2025
Q3 		– Sell
-12,947
Closed -$15.5K – 641
2025
Q2 		$15.5K Buy
+12,947
New +$14.4K 0.01% 450

Other funds holding LAB

CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
MCO
MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HBWM
Hollow Brook Wealth Management Katonah, New York $392M AUM 36.68% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

R Squared's LAB Position: Q1 2026 in Review

R Squared opened a new position in Standard BioTools (LAB) in Q1 2026: 10,268 shares worth $9.44K. The stake represents 0.01% of the portfolio and ranks #471 among its holdings. This is a return to the name: R Squared previously reported a position in LAB as recently as Q2 2025.

R Squared first reported a position in LAB in Q2 2025 and has held it in 2 quarters since. The position peaked at $15.5K in Q2 2025. 155 funds tracked by Wall St. Rank hold LAB as of Q1 2026.

  • R Squared held 10,268 shares of Standard BioTools worth $9.44K as of Q1 2026.
  • Standard BioTools was a new R Squared position in Q1 2026.
  • Standard BioTools made up 0.01% of R Squared's portfolio in Q1 2026, its #471 holding.
  • R Squared first reported a position in Standard BioTools in Q2 2025 and has held it in 2 quarters since.
  • R Squared's Standard BioTools position peaked at $15.5K in Q2 2025.
  • 155 funds tracked by Wall St. Rank held Standard BioTools as of Q1 2026.

Based on R Squared's 13F filing for Q1 2026, filed 29 Apr 2026.